HOME >> MEDICINE >> NEWS
Takeda submits new drug application for extended-release type 2 diabetes medication, ACTOplus met

LINCOLNSHIRE, Ill. Takeda Global Research & Development Center (TGR&D) today announced that the company has submitted a New Drug Application (NDA) for an extended-release version of the combination medication ACTOplus met TM (pioglitazone HCl and metformin HCl) to the United States Food and Drug Administration (FDA) for the treatment of type 2 diabetes. This new formulation (ACTOplus met XR) would allow for once-daily dosing, while ACTOplus met (immediate release) is already available, being marketed by Takeda Pharmaceuticals North America, Inc.

ACTOplus met is an oral medication that combines ACTOS (pioglitazone HCl), which directly targets insulin resistance a condition in which the body does not efficiently use the insulin it produces with metformin, which acts primarily by reducing the amount of glucose produced by the liver. These medications work in combination to help patients with type 2 diabetes manage their blood glucose levels.

The NDA submission represents yet another milestone for Takeda, following the FDA approval of ROZEREMTM(ramelteon).

"We are certainly proud of this NDA submission, and the ACTOS portfolio of products," said John Yates, M.D., president of TGR&D. "Not all patients are alike, especially in diabetes, and the addition of this new product would provide patients and their physicians with more options and greater flexibility, while continuing to provide the benefits of treatment with ACTOS." Extended-release metformin, one of the active ingredients in ACTOplus met XR, was developed by Andrx Corporation. Takeda Pharmaceutical Company Limited signed an agreement with Andrx Corporation covering extended-release metformin in December 2003.


'"/>


3-Apr-2006


Page: 1

Related medicine news :

1. Takeda responds to the FDA advisory committee recommendation
2. Takeda submits new drug application for combination type 2 diabetes medication
3. Sucampo Pharmaceuticals submits supplemental new drug application for Lubiprostone to treat IBS-C
4. Sucampo submits new drug application for lubiprostone
5. Brightening prospects of using fluorescent nanotubes in medical applications
6. Panbio files first patent application for Homogenous Assay Technology
7. LOral accepting applications for 2007 USA fellowships for Women in Science
8. NIH wrongly blamed for reduced success rate of grant applications
9. Magnet lab researcher exploring science behind commercial applications of liquid helium
10. Dalai Lama, top scientists to discuss science & clinical applications of meditation
11. Mechanism controlling DNA damage response has potential novel medical applications

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/13/2019)... ... June 13, 2019 , ... In Partnership with the Smiles for ... underinsured individuals at its Mesquite, TX office on July 13th. , Dental services provided ... and extractions . For more information, please visit the Monarch Dental website ...
(Date:6/13/2019)... ... 13, 2019 , ... In two nationally representative surveys of parents and principals ... impact movement Active Schools aimed to gain a better understanding of ... , The U.S. Department of Health and Human Services recommends that children and ...
(Date:6/13/2019)... FAIRFAX, Va. (PRWEB) , ... June 13, 2019 ... ... Business Awards® , has announced that the final entry deadline in the 2019 ... 12. , Recognized as the world’s premier business awards program, The IBAs ...
(Date:6/13/2019)... ... 2019 , ... GlycoMark, Inc. announced a new study “GlycoMark ... (ADA) Scientific Sessions 2019 involving the GlycoMark test being used for patients with ... are used to lower glucose levels in patients with diabetes by preventing glucose ...
(Date:6/12/2019)... (PRWEB) , ... June 12, 2019 , ... ... cannabis product label experts, get valuable advice on innovative branding and network with ... marketing? Business owners, scientists, media representatives, farmers, nutritionists, manufacturers and others who are ...
Breaking Medicine News(10 mins):
(Date:6/13/2019)... ... June 13, 2019 , ... IPVideo ... passive visual weapons detection systems, is proud to announce its verified integration with ... a verified technology partner IPVideo’s award-winning HALO sensor is now available on the ...
(Date:6/13/2019)... ... 2019 , ... Homecare Homebase (HCHB) the nation’s leader in ... part of the HCHB Intelligence Suite, at the company’s annual Users Conference this ... highly efficient routing, mapping and scheduling for home health agencies to automate the ...
(Date:6/13/2019)... ... June 13, 2019 , ... Access Healthcare , a ... be attending and exhibiting at the HFMA Annual Conference 2019 which will ... President (US Operations) of Access Healthcare, says, “HFMA Annual Conference has inspired us in ...
Breaking Medicine Technology:
Cached News: